GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Mirabegron (Myrbetriq)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

MYRBETRIQ (mirabegron) extended-release tablets

Product / population
Adult overactive bladder; extended-release tablets only, not pediatric granules.
Renal measure
Not specified; verify before use
Adult oral regimen

Start 25 mg once daily. An increase to 50 mg daily may be made after 4-8 weeks when indicated. Tablets and granules are not interchangeable milligram-for-milligram.

Labeled renal limits

Table 2 uses MDRD eGFR in mL/min/1.73 m2. At 30-89, start 25 mg/day and allow at most 50 mg/day. At 15-29, both starting and maximum doses are 25 mg/day. Below 15 or during hemodialysis, use is not recommended.

Source revision: | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d

Scope: Source-read local summary; source-specific recommendations are not automatically interchangeable. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

MYRBETRIQ (mirabegron) extended-release tablets

Adult overactive bladder; extended-release tablets only, not pediatric granules.

Renal method: See source.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition

Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: See source.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeMYRBETRIQ (mirabegron) extended-release tabletsRenal Drug Handbook, fifth edition
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The handbook includes historical dosing below GFR 15 and during dialysis. The selected U.S. adult tablet label does not recommend use below eGFR 15 or during hemodialysis; the handbook is not an override.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/medications-with-general-renal-dosing-statements/

GlobalRPh general renal statement

Dosing Information: The recommended starting dose of Myrbetriq is 25 mg once daily with or without food. Myrbetriq 25 mg is effective within 8 weeks. Based on individual patient efficacy and tolerability the dose may be increased to 50 mg once daily. Myrbetriq should be taken with water, swallowed whole and should not be chewed, divided, or crushed.

Dose Adjustments in Specific Populations: The daily dose of Myrbetriq should not exceed 25 mg once daily in the following populations: Patients with severe renal impairment (CLcr 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m2). Patients with moderate hepatic impairment (Child-Pugh Class B).

Myrbetriq is not recommended for use in patients with end stage renal disease (ESRD), or in patients with severe hepatic impairment (Child-Pugh Class C).

GRPH-general-mirabegron-01 · Source section: GlobalRPh general renal statementRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

MYRBETRIQ (mirabegron) extended-release tablets

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Adult overactive bladder; extended-release tablets only, not pediatric granules.

Renal method: Not specified in this summary.
Source date:
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Adult oral regimen

Start 25 mg once daily. An increase to 50 mg daily may be made after 4-8 weeks when indicated. Tablets and granules are not interchangeable milligram-for-milligram.

general-mirabegron:dm-ba9e9e15-e666-4c56-9271-2e24739cfa2d-1 · Source locator: 2.1; 2.2

Labeled renal limits

Table 2 uses MDRD eGFR in mL/min/1.73 m2. At 30-89, start 25 mg/day and allow at most 50 mg/day. At 15-29, both starting and maximum doses are 25 mg/day. Below 15 or during hemodialysis, use is not recommended.

general-mirabegron:dm-ba9e9e15-e666-4c56-9271-2e24739cfa2d-2 · Source locator: 2.4, Table 2

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d
Retrieved
2026-09-05
Exact label title
MYRBETRIQ (mirabegron) extended-release tablets
DailyMed Set ID
ba9e9e15-e666-4c56-9271-2e24739cfa2d
Labeler
Astellas Pharma US, Inc.
DailyMed page updated
2024-08-01
FDA application
NDA marketing category
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
81d3ebd98ae2d7b043b99b34bb085976e95e561b5ec37758301ae7fefa890617
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition

Open / share this exact local source

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Historical renal bands

GFR 30-60 mL/min: usual dose, or 25 mg with CYP3A inhibitors. At 15-29, the book lists 25 mg daily and avoidance with CYP3A inhibitors. It also lists 25 mg below 15, with the same interaction caution.

general-mirabegron:rdh5-663-1 · Source locator: Dose in renal impairment

Historical renal-replacement comments

The book considers removal unlikely across APD/CAPD, HD, high-flux HDF and CAV/VVHD, referring the first three to <15 and CAV/VVHD to 15-29.

general-mirabegron:rdh5-663-2 · Source locator: Dose in renal replacement

Source-specific limits

The selected U.S. adult tablet label does not recommend treatment below eGFR 15 or on hemodialysis. The book's below-15 and dialysis doses are historical source differences, not endorsed replacement protocols.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 663; PDF page 682
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
7fdc14e013014fab28634985209346ad764d335ccd9f949373e0b3a0fa685365

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/medications-with-general-renal-dosing-statements/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph general · Numbered general entry 15
Local text SHA-256
2f142a1e96e1f90a98e215a688e5d974a0be2900f120c0b521581c7eed3748fe
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report